Aptevo Therapeutics closed at $1.37 on Nov 4, up 0.74%, 95.1% below its 52-week closing high. Volume of 14.8K shares was 0.33× its 20-day average (below normal).
Split-adjusted performance: -23.7% over one month, -72.3% over six months, -94.8% over one year.
Short interest was 96.5K shares at the Oct 15 settlement, down 19.2% from the prior report (5.8% of float, 1.9 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| APVOAptevo Therapeutics | $1.37 | +0.74% | −72.3% | — | — | — | $2.5M | |
| HCWBHCW Biologics | $1.08 | −6.09% | −48.6% | +1969.7% | −11340.3% | — | $2.4M | Compare |
| REVBRevelation Biosciences | $4.12 | −7.05% | −42.3% | — | — | — | $2.3M | Compare |
| ERNAErnexa Therapeutics | $1.99 | −1.49% | −67.1% | — | — | — | $2.3M | Compare |
| SILOSilo Pharma | $1.33 | +3.91% | −78.9% | −100.0% | — | — | $2.9M | Compare |
| GRIGRI Bio | $1.43 | −7.14% | −39.4% | — | — | — | $3.1M | Compare |
| SBFMSunshine Biopharma | $2.65 | −3.28% | −98.8% | −1.6% | −16.9% | — | $2.0M | Compare |
| MBIOMustang Bio | $0.4138 | +1.07% | −44.6% | — | — | — | $3.1M | Compare |
| JUNSJupiter Neurosciences | $2.46 | +1.23% | −91.0% | — | −9380.9% | — | $3.2M | Compare |
No recent articles focused on Aptevo Therapeutics.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
